EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Peep into anti-vascular endothelial growth factor

Lalit Verma, Shweta Singh, Obuli Ramachandran

Indian Journal of Ophthalmology · 2026-05 · 74 (5) · 635-638

DOI: 10.4103/ijo.ijo_385_26 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Indian Journal of Ophthalmology, online erschienen am 29.04.2026. Verfasst von Lalit Verma und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Vitreo Retinal Services, Centre for Sight Eye Institute, Dwarka, New Delhi, India. Hauptthemen laut MEDLINE: Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anti-vascular endothelial growth factor (anti-VEGF) therapy has transformed the management of retinal vascular diseases over the past two decades. Beginning with the foundational identification of VEGF as the principal driver of ocular neovascularization, the field has evolved from early agents such as pegaptanib and bevacizumab to more potent molecules including ranibizumab, aflibercept, brolucizumab, and faricimab. In India, the landscape is shaped by unique economic and epidemiological factors, including a high burden of diabetic retinopathy and age-related macular degeneration, limited healthcare reimbursement, and the significant role of biosimilar ranibizumab products in expanding access. This article provides a comprehensive overview of the historical development, pharmacology, regulatory milestones, safety considerations, and current clinical use of anti-VEGF agents in the Indian context, with emphasis on strategies to deliver equitable, high quality retinal care across a diverse population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiogenesis InhibitorsVascular Endothelial Growth Factor AHumansIntravitreal InjectionsRanibizumab

Stichwörter der Autor:innen

Anti-VEGFbevacizumabbiosimilarsdiabetic macular edemaranibizumab

Substanzen

Angiogenesis InhibitorsVascular Endothelial Growth Factor ARanibizumab

Autor:innen und Institutionen

  • Department of Vitreo Retinal Services, Centre for Sight Eye Institute, Dwarka, New Delhi, India.

Zitieren

APA

Verma, L., Singh, S., & Ramachandran, O. (2026). Peep into anti-vascular endothelial growth factor. Indian Journal of Ophthalmology, 74(5), 635-638. https://doi.org/10.4103/ijo.ijo_385_26

Vancouver

Verma L, Singh S, Ramachandran O. Peep into anti-vascular endothelial growth factor. Indian Journal of Ophthalmology. 2026;74(5):635-638. doi:10.4103/ijo.ijo_385_26

BibTeX
@article{Verma2026,
  author = {Verma, Lalit and Singh, Shweta and Ramachandran, Obuli},
  title = {Peep into anti-vascular endothelial growth factor},
  journal = {Indian Journal of Ophthalmology},
  year = {2026},
  volume = {74},
  number = {5},
  pages = {635--638},
  doi = {10.4103/ijo.ijo_385_26}
}
Kostenlos starten →